About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Enrolling By InvitationNCT07122882

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Currently, tyrosine kinase inhibitor (TKI) remains the standard of care for oncogene-driven non-small cell lung cancer (NSCLC). However, almost all oncogene-driven NSCLCs would develop acquired resist...

Lead sponsor: Chang Gung Memorial Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Chang Gung Memorial Hospital

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Histologically confirmed NSCLC, with at least one of the known oncogene mutation prior to systemic treatment: EGFR exon 18-21 activating mutation, MET exon-14-skipping mutation, ERBB2 activating mutation, ALK fusion, ROS1 fusion, RET fusion, NTRK1 fusion, NTRK2 fusion, NTRK3 fusion, BRAF V600 mutation, or KRAS G12C mutation
•2. Patient had received tyrosine kinase inhibitor (TKI) with progressive disease, as assessed by the treating physician
•3. Had tumor tissue available for DNA extraction and sequencing.
•4. Eligible for withdrawal of a blood sample for DNA extraction and sequencing.

Exclusion Criteria

•1. Patient had not received TKI or did not have documented disease progression during TKI treatment.
•2. Tumor tissue was unavailable for DNA extraction or the DNA quality did not meet the sequencing requirement.

Related studies

RECRUITINGPhase 1

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

NCT07315113 · EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients

RECRUITINGPhase 2

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

NCT06668103 · Non-Small Cell Lung Cancer With EGFR Mutation

RECRUITINGPhase 2

Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

NCT06728865 · Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, and more

Active Not RecruitingPhase 1

A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

NCT05514496 · EGFR Mutation-Related Tumors

Not Yet RecruitingPhase 2

High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

NCT06971406 · Non Small Cell Lung Cancer, EGFR Mutation, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 17, 2026Terms

Trial snapshot

StatusENROLLING_BY_INVITATION

Phase—

Enrollment40

Start dateSep 2025

Last updatedMar 17, 2026

Condition

Oncogene-addicted Non Small Cell Lung Cancer EGFR Mutation ALK Fusion-positive Solid or CNS Tumors ROS1 Fusion Positive RET Fusion Positive+8 more

Locations shown

Chang Gung Memorial Hospital Linkou Branch

Taoyuan District

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions